GlaxoSmithKline to Pay $229M to Settle Diabetes Drug Suit

by William White | July 25, 2013 11:37 am

GlaxoSmithKlineLogo GlaxoSmithKline to Pay $229M to Settle Diabetes Drug Suit[1]GlaxoSmithKline (GSK[2]) announced Wednesday[3], that it will spend $229 million to settle lawsuits concerning deceptive marketing of its diabetes drug Avandia.

The company agreed to the settlement price with attorney generals of eight states: Kentucky, Louisiana, Maryland, Mississippi, New Mexico, South Carolina, Utah and West Virginia. The states chose not to take a settlement of $90 million offered in 2012, which resolved  Avandia-related consumer-protection claims by 37 other states, reports The Wall Street Journal.

Last year Glaxo pleaded guilty in federal court for failing to provide the Food and Drug Administration with clinical-trial information concerning Avandia. The company paid $3 billion to resolve federal investigations of the company, reports WSJ.

The $3 billion settlement is the largest to date in a health-care fraud case in the U.S., reports Bloomberg[4].

Avandia was removed from the European market [5]in 2010, and has since been heavily restricted in the United States.

  1. [Image]:
  2. GSK:
  3. announced Wednesday:
  4. Bloomberg:
  5. removed from the European market :,0,2169732.story

Source URL:
Short URL: